The DVL2 Knockout NCI-H1299 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt expression of the human DVL2 gene in the NCI-H1299 epithelial cell background. This heterogeneous population, generated by CRISPR/Cas9-mediated target-gene disruption, provides a valuable loss-of-function model for investigating DVL2-dependent signaling mechanisms. DVL2, encoding dishevelled segment polarity protein 2, functions as a cytoplasmic phosphoprotein and essential scaffold in Wnt signaling cascades. The polyclonal format offers a robust tool for studying DVL2 function without single-cell clonal isolation, enabling immediate application in pathway interrogation and functional assays.
The NCI-H1299 host cell line is a widely used human non-small cell lung cancer (NSCLC) model derived from the lymph node metastasis of a lung adenocarcinoma. This epithelial cell line is characterized by p53 deficiency and wild-type KRAS, representing a genetic context relevant to a subset of NSCLC tumors. Its metastatic origin and established role in cancer biology make it particularly suitable for studying tumor progression, migration, and epithelial-mesenchymal transition (EMT). The combination of DVL2 knockout with the NCI-H1299 background creates a powerful system to dissect Wnt pathway contributions in lung cancer without confounding KRAS mutations.
At the molecular level, DVL2 acts as a central hub in Wnt/??-catenin and Wnt/planar cell polarity (PCP) pathways. Upon Wnt ligand binding (e.g., Wnt3a or Wnt5a) to Frizzled receptors and LRP5/6 co-receptors, DVL2 is recruited to the plasma membrane, where it interacts with AXIN, GSK3??, and casein kinase 1 (CK1) to inhibit the ??-catenin destruction complex. This leads to stabilization and nuclear accumulation of ??-catenin, which partners with TCF/LEF transcription factors to drive expression of target genes such as MYC and CCND1. In parallel, DVL2 can activate PCP signaling via downstream effectors including RhoA/ROCK and JNK, regulating cytoskeletal dynamics and cell motility, as well as the Wnt/Ca2+ pathway through NFAT. DVL2 also homodimerizes or heterodimerizes with DVL1 and DVL3, and interacts with VANGL and PRICKLE to coordinate polarity signaling.
The loss of DVL2 in NCI-H1299 cells is expected to impair both ??-catenin-dependent transcriptional output and PCP-mediated migratory processes, providing an experimentally tractable model for lung cancer research. Given the p53-deficient background, this knockout system is particularly useful for investigating how Wnt pathway alterations intersect with p53 loss in tumor progression, therapeutic resistance, and EMT. Researchers can employ this model to assess DVL2’s role in mediating Wnt-driven proliferation, invasion, and the response to chemotherapeutic agents, thereby addressing key questions in NSCLC biology.
Typical applications include measuring ??-catenin transcriptional activity using luciferase reporter assays, quantifying active ??-catenin levels and DVL2 phosphorylation shifts by Western blotting, and monitoring Wnt target gene expression changes (MYC, CCND1) via RT-qPCR. Functional studies can examine alterations in cell migration and invasion through wound healing or Transwell assays, while co-immunoprecipitation experiments can probe disrupted DVL2 interactions with AXIN or Frizzled receptors. Immunofluorescence for DVL2 puncta formation can further characterize signaling complex integrity. This knockout polyclonal population supports a wide range of mechanistic investigations into Wnt signaling in cancer and drug development. For additional information or custom requests, please contact Ascent Research.
